AARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotech spin-off from the University of Valencia developing targeted RNA medicines that modulate microRNAs to treat rare genetic neuromuscular diseases. Its lead program, ATX-01, is in Phase I/IIa trials (ArthemiR) for myotonic dystrophy type 1 (DM1) following FDA clearance in 2024. The company closed an upsized $87M Series B in 2025 led by Bpifrance.
SectorsBiotechnology, RNA therapeutics, Rare disease, Neuromuscular disorders
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
B
Beatriz Llamusí
Chief Scientific Officer & Co-Founder
R
Rubén Artero
Co-Founder
Global models 5
SSkyhawk Therapeutics
United States · www.skyhawktx.com ↗
Develops small-molecule and oligonucleotide RNA-modulating therapeutics for genetic diseases, the same RNA-targeting therapeutic model as ARTHEx.
$181MComparable
DDyne Therapeutics
United States · www.dyne-tx.com ↗
Develops oligonucleotide therapeutics specifically for serious muscle diseases, directly paralleling ARTHEx's neuromuscular RNA medicine focus.
$166MComparable
AAvidity Biosciences
United States · www.aviditybiosciences.com ↗
Uses RNA-conjugate therapeutics to target myotonic dystrophy (DM1) and other muscle diseases, the same indication and RNA-modality as ARTHEx's lead program.
$143MComparable
WWave Life Sciences
United States · www.wavelifesciences.com ↗
Develops stereopure oligonucleotide drugs to modulate RNA for genetic diseases, closely matching ARTHEx's oligonucleotide-based therapeutic platform.
$84MComparable
MmiRagen Therapeutics
United States · www.miragen.com ↗
Developed microRNA-targeted therapeutics, the most direct model match to ARTHEx's anti-miR (antisense microRNA) approach.
$72MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 12
Open as list →
IInvivo Partners
invivo.partners
CColumbus Venture Partners
columbusvp.com
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
EEIC Fund
eic.ec.europa.eu
AAlta Life Sciences
altals.com
A
Advent France Biotechnology
B
Bpifrance
AAdBio Partners
HHadean Ventures
SSound Bioventures
AAdvent Life Sciences
S
Sanofi Ventures
Funding rounds 4
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-17 | Series B | $87M |
Bpifrance
+7 more
|
| 2023-05-03 | Series B | €42M |
Columbus Venture Partners
+6 more
|
| 2020-07-23 | Series A | €4.25M | Invivo Ventures, Advent France Biotechnology |
| 2020-01-08 | Seed | €2.7M |
Invivo Ventures
+1 more
|